Pharmaceutical

FDA approves Accord BioPharma’s HERCESSI for cancer treatment

Accord BioPharma received FDA approval for 420mg HERCESSI, a biosimilar to Herceptin to treat various kinds of HER2-overexpressing cancers.

Sep 20, 2024 - 04:00
FDA approves Accord BioPharma’s HERCESSI for cancer treatment
Accord BioPharma received FDA approval for 420mg HERCESSI, a biosimilar to Herceptin to treat various kinds of HER2-overexpressing cancers.
Read the original article

Tags:

Previous Article

Lupin and Takeda to commercialise Vonoprazan in India

Next Article

Top three trends in precision medicine

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Pharmalittle: Deadline looms for drugmakers to negotiate with Medicare; GOP senator probes 340B program at two hospitals

STAT+: Pharmalittle: Deadline looms for drugmakers to n...

Sep 30, 2023

STAT+: 3 CRISPR advances to watch in 2024

STAT+: 3 CRISPR advances to watch in 2024

Dec 27, 2023

STAT+: Drugs are still mostly tested in white men. Will the FDA change that next year?

STAT+: Drugs are still mostly tested in white men. Will...

Dec 21, 2023